Bristol-Myers Squibb Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(I.R.S Employer Identification No.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
||
|
||
|
Item 7.01
|
Regulation FD Disclosure.
|
Item 9.01
|
Financial Statements and Exhibits.
|
Exhibit
No.
|
Description
|
|
Investor presentation of Bristol-Myers Squibb Company dated January 13, 2025.
|
||
104
|
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
|
BRISTOL-MYERS SQUIBB COMPANY
|
|||
Dated: January 13, 2025
|
By:
|
/s/ Amy Fallone
|
|
Name:
|
Amy Fallone
|
||
Title:
|
Corporate Secretary
|